Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
Loading...
Date
Authors
Nicolaides, C.
Giannakakis, T.
Skarlos, D.
Athanassiadis, A.
Fountzilas, G.
Damigos, D.
Pavlidis, N.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Journal of Experimental & Clinical Cancer Research
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Tropisetron is a novel selective antagonist of the type-3 serotonin (5-HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m(2) has a high emetogenic potential. This study was designed to determine whether a single intravenous administration of tropisetron could prevent acute nausea and vomiting in patients treated with high dose: epirubicin. Forty chemotherapy naive breast cancer patients treated with epirubicin at a dose of 110 mg/m(2) on an outpatient basis were enrolled in the study. Tropisetron 5 mg i.v. was used as antiemetic prophylaxis. "On demand" treatment with tropisetron 5 mg p.os was used for the rescue of patients who failed on the initial iv dose. Complete control of acute nausea and vomiting had 62.5% (95% C.1, 47.2 - 77.8), partial control 15% (95% C.1, 3.8-26.2) and 22.5% (95% C.1. 9.3-35.7) insufficient control or failure. Headache was the most common adverse event reported in 3 patients (7.5%) and constipation in 2 patients (5%). Interestingly, patients with a negative experience of nausea and vomiting during pregnancy and those treated for metastatic disease, had a better control of chemotherapy-induced nausea and vomiting. In conclusion, a single 5 mg i.v. dose of tropisetron is safe and effective in preventing acute emesis in patients treated with high dose epirubicin.
Description
Keywords
5-ht3 receptor antagonist, tropisetron, acute emesis, high dose epirubicin, antiemetic agents, induced emesis, ics 205-930, chemotherapy, ondansetron, antagonist
Subject classification
Citation
Link
<Go to ISI>://000073534200010
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής